ACM
BBIO icon

Aster Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Aster Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$707K Buy
+9,491
New +$665K 0.15% 204
2025
Q4 		– Sell
-588
Closed -$30.5K – 1107
2025
Q3 		$30.5K Buy
+588
New +$28.7K 0.02% 599

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Aster Capital Management's BBIO Position: Q2 2026 in Review

Aster Capital Management opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 9,491 shares worth $707K. The stake represents 0.15% of the portfolio and ranks #204 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in BBIO as recently as Q3 2025.

Aster Capital Management first reported a position in BBIO in Q3 2025 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Aster Capital Management held 9,491 shares of BridgeBio Pharma worth $707K as of Q2 2026.
  • BridgeBio Pharma was a new Aster Capital Management position in Q2 2026.
  • BridgeBio Pharma made up 0.15% of Aster Capital Management's portfolio in Q2 2026, its #204 holding.
  • Aster Capital Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 2 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.